Scisparc Ltd
NASDAQ:SPRC
Scisparc Ltd
Other Items
Scisparc Ltd
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Scisparc Ltd
NASDAQ:SPRC
|
Other Items
-$1.6m
|
CAGR 3-Years
-244%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-32%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Other Items
$8k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-46%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Other Items
$11.5m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Other Items
$94.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Other Items
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Matricelf Ltd
TASE:MTLF
|
Other Items
₪9.9m
|
CAGR 3-Years
635%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Scisparc Ltd
Glance View
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The firm is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
See Also
What is Scisparc Ltd's Other Items?
Other Items
-1.6m
USD
Based on the financial report for Dec 31, 2024, Scisparc Ltd's Other Items amounts to -1.6m USD.
What is Scisparc Ltd's Other Items growth rate?
Other Items CAGR 10Y
-32%
Over the last year, the Other Items growth was -47%. The average annual Other Items growth rates for Scisparc Ltd have been -244% over the past three years , and -32% over the past ten years .
